Xencor claims that a proprietary suite of XmAb Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation.
As part of its license agreement, Boehringer Ingelheim has also exercised an option to utilize XmAb High ADCC technology for a second discovery program in oncology against an undisclosed target.
Xencor CEO Bassil Dahiyat said that their partners continue to move Fc engineered antibodies into the clinic optimised for heightened potency and convenient dosing, important attributes when differentiating from existing agents and biosimilars.
"Our XmAb technology is also fueling Xencor’s internal pipeline, which includes several optimised antibodies for both oncology and autoimmune diseases," Dahiyat said.